The cytokines and the B-cell malignancies: a new spin on maximizing therapeutic outcomes.
Snively
Anne H
AH
Oncology Nursing Society, Pittsburgh, PA, USA.
D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D058846:Antibodies, Monoclonal, Murine-Derived; D000920:Antibody-Dependent Cell Cytotoxicity; D000970:Antineoplastic Agents / Q000627:therapeutic use; D016207:Cytokines / Q000627:therapeutic use*; D018572:Disease-Free Survival; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000627:therapeutic use; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000175:diagnosis / Q000628:therapy*; D016393:Lymphoma, B-Cell / Q000175:diagnosis / Q000628:therapy*; D008224:Lymphoma, Follicular / Q000175:diagnosis / Q000628:therapy*; D016403:Lymphoma, Large B-Cell, Diffuse / Q000175:diagnosis / Q000628:therapy*; D009367:Neoplasm Staging; D009859:Oncology Nursing / Q000458:organization & administration; D011379:Prognosis; D012074:Remission Induction; D000069283:Rituximab
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents; D016207:Cytokines; D007155:Immunologic Factors; D000069283:Rituximab; D016178:Granulocyte-Macrophage Colony-Stimulating Factor